Latest Breaking News On - Davidg watumull - Page 1 : comparemela.com

Cardax Reports Q1 2021 Results - Operating loss decreased vs. Q1 2020 - Net loss increased vs. Q1 2020 - ZanthoSyn® revenues decreased vs. Q1 2020 - Company pursuing multiple funding opportunities News provided by Share this article HONOLULU, May 14, 2021 /PRNewswire/  Cardax, Inc. (OTCQB:CDXI) reported its Q1 2021 results. Highlights: Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312 in Q1 2021 primarily due to reduced salaries & wages, professional fees, stock based compensation, and selling, general, & administrative expenses. Other expenses increased from $96,837 in Q1 2020 to $610,806 in Q1 2021, primarily due to a non-cash reduction in the gain from modification of debt instruments and a non-cash change in the fair value of the derivative liability. Net loss increased from $1,002,868 in Q1 2020 to $1,382,118 in Q1 2021.

HonoluluHawaiiUnited statesDavidg watumullJanice kamExchange commissionCardax incSmall business administration economic injury disaster loanDrug administrationSecurities exchangeNutrition corporationCardiovascular health astaxanthin supplement evaluationGeneral nutrition corporationSmall business administrationEconomic injury disaster loanQuarterly report